Point72 Asset Management
OVID icon

Point72 Asset Management’s Ovid Therapeutics OVID Stock Holding History

Point72 Asset Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93M Sell
1,320,610
-2,230,519
-63% -$3.99M ﹤0.01% 2059
2025
Q4 		$5.79M Buy
+3,551,129
New +$5.47M 0.01% 1730

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management's OVID Position: Q1 2026 in Review

Point72 Asset Management reduced its Ovid Therapeutics (OVID) stake by 63% in Q1 2026, selling an estimated $3.99M and leaving 1,320,610 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2059.

Point72 Asset Management first reported a position in OVID in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.79M in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Point72 Asset Management held 1,320,610 shares of Ovid Therapeutics worth $2.93M as of Q1 2026.
  • Point72 Asset Management sold 2,230,519 Ovid Therapeutics shares in Q1 2026, an estimated $3.99M.
  • Ovid Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2059 holding.
  • Point72 Asset Management first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Point72 Asset Management's Ovid Therapeutics position peaked at $5.79M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.